Click Holdingsの空売り状況は、投資家がClick Holdingsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Click Holdings (NASDAQ:CLIK) 株価情報, 空売り情報

Click Holdings Ltd is a human resources solutions provider, specializing in offering comprehensive human resources solutions. It is focused on talent sourcing and the provision of temporary and permanent personnel to customers and also in placing professional accountants and company secretaries, registered nurses and healthcare workers as well as other blue-collar workers, for direct hire and contract staffing roles. The Company operates in three segments, 1) professional solution services, 2) nursing solution services and 3) logistic and other solution services. Maximum revenue is generated from Professional solution services and Hong Kong.

Click Holdings Ltd

Summer is almost here, and investors are hunting for fresh opportunities after the S&amp;P 500 logged its strongest <a href="https://www.benzinga.com/markets/equities/25/05/45704748/magnificent-seven-drive-wall-streets-rally-nvidia-notches-best-month-in-a-year-this-week-in-markets">month since November 2023. </a>
According to Seasonax data, looking at 97 years of history, the S&amp;P 500 averages a 0.7% gain in June. In recent times, performance has been even better: over the past six years, the index has ended June higher five times, with an average return of 2.1%.
Thus, June has historically brought more gains than pain, and certain S&amp;P 500 stocks have a consistent track record of outperforming in this early-summer stretch.
<h3 class="wp-block-heading">Top 10 June Stocks Based On 10-Year Seasonal Performance</h3>
An analysis of S&amp;P 500 components between June 2 and July 2 over the past 10 years reveals clear outperformers. Here are the top 10 stocks ranked by average return during this 30-day window. 
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is by far the top June performer, with an average return of 14.5%, beating the S&amp;P 500 by a wide margin. It closed positively in 8 out of the last 10 Junes, with the best return — a 37.1% rally — coming in 2023.
Eli Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has been the most consistent performer on this list, with 9 wins in 10 years. Its June gains have averaged 6.2% over the past decade, with a peak return of 17.5% in 2021 and a minimal drawdown of -2.2% in 2019.
Adobe Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) also ranks high with a 5.6% average return. Notably, in the last two Junes, the tech company rose by 17% and 24.9% respectively.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Stock</th>
<th>Avg Return</th>
<th>Win Rate</th>
<th>Max Gain</th>
<th>Worst Drop</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tesla </td>
<td>+14.5%</td>
<td>8/10</td>
<td>+37.1%</td>
<td>-9.8%</td>
</tr>
<tr>
<td>Eli Lilly </td>
<td>+6.2%</td>
<td>9/10</td>
<td>+17.5%</td>
<td>-2.2%</td>
</tr>
<tr>
<td>Adobe </td>
<td>+5.7%</td>
<td>6/10</td>
<td>+29.3%</td>
<td>-14.7%</td>
</tr>
<tr>
<td>Oracle Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NASDAQ">ORCL</a>)</td>
<td>+4.9%</td>
<td>7/10</td>
<td>+20.1%</td>
<td>-7.6%</td>
</tr>
<tr>
<td>Generac Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>)</td>
<td>+4.9%</td>
<td>6/10</td>
<td>+31.2%</td>
<td>-19.4%</td>
</tr>
<tr>
<td>Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</td>
<td>+4.3%</td>
<td>7/10</td>
<td>+16.9%</td>
<td>-9.6%</td>
</tr>
<tr>
<td>Digital Realty Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>)</td>
<td>+4.0%</td>
<td>7/10</td>
<td>+15.5%</td>
<td>-6.2%</td>
</tr>
<tr>
<td>Domino's Pizza Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>)</td>
<td>+4.0%</td>
<td>6/10</td>
<td>+11.5%</td>
<td>-5.5%</td>
</tr>
<tr>
<td>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)</td>
<td>+3.7%</td>
<td>5/10</td>
<td>+17.0%</td>
<td>-7.7%</td>
</tr>
<tr>
<td>Fair Isaac Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>)</td>
<td>+3.7%</td>
<td>8/10</td>
<td>+18.2%</td>
<td>-1.96%</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/06/45722678/magnificent-seven-closed-a-blockbuster-may-added-nearly-2-trillion-in-market-value">Magnificent Seven Closed A Blockbuster May, Added Nearly $2 Trillion In Market Value </a></li>
</ul>
Photo: Shutterstock

Large Cap

AAPL

ADBE

AMZN

FICO

GNRC

ORCL

TSLA

Looking For Summer Seasonal Gains? Here Are 10 S&P 500 Stocks That Historically Rallied In June

WIIM

STLA

Shares of automobile companies are trading lower. The industry may be facing weakness due to steel tariffs and investor concerns about overseas prices.

News

Rumors

Trading Ideas

CTLP

Watching Cantaloupe; Shares Spike Higher, Traders Circulate Unconfirmed Report That The Company Has Seen Multiple Takeover Bids As Final Deal Nears

NIVF

NIVF stock has given up its prior gain. NewGenIvf Group shares were trading higher after the company announced a $30 million investment in Solana Digital Asset staking.

Billionaire investor <a href="https://www.benzinga.com/news/25/03/44375147/smart-puppies-are-smarter-than-ai-mark-cubans-surprising-take-on-the-future-of-artificial-intelligence">Mark Cuban</a> definitely loves it, and television finally caught the grin as he cracked open his last-ever "Shark Tank" deal with a startup that sells nothing but deviled eggs.&nbsp;
Viewers watched the longtime shark pair with real-estate titan Barbara Corcoran to offer $250,000 for 20% of Deviled Egg Co., proving the humble picnic side can still hatch serious money. "I definitely love it," Cuban said during the pitch, sealing his final deal with trademark enthusiasm.&nbsp;
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
</ul>
His goodbye slice of capitalism was served with crab-rangoon filling and nationwide ambition. Reflecting on his journey during the <a href="https://youtu.be/nGH1ZIzLg24">Season 16 finale</a>, taped in January and aired May 16, on "Shark Tank," <a href="https://people.com/how-mark-cuban-said-goodbye-shark-tank-final-episode-11736969">Cuban remarked</a>, "This show changed me. I think I changed the show. And I think we all together as Sharks changed America."
<h2 class="wp-block-heading">Cracking The Egg Market</h2>
Former lounge manager Raechel Van Buskirk began experimenting with off-beat deviled eggs in 2017, selling trays from her Omaha kitchen. <a href="https://www.cnbc.com/2025/05/20/mark-cuban-final-shark-tank-deal-deviled-egg-co.html">According to CNBC</a>, she teamed with early investor Alexi Wellman three years later to roll out a food trailer.&nbsp;
Van Buskirk, who relocated to Dallas after a December 2022 breast cancer diagnosis so she could be near family, closed the original Omaha, Nebraska, shop in 2024 and is now in full remission. By the time the duo wheeled onto TV, Deviled Egg Co. had <a href="https://sharktankrecap.com/deviled-egg-co-update-shark-tank-season-16/">tallied nearly $1.3 million</a> in 2024 revenue and was already profitable, Van Buskirk said during her pitch.&nbsp;
The founders asked for $150,000 in exchange for 5% equity, outlining plans to open two grab-and-go outlets and eventually franchise across Texas.&nbsp;
Trending: <a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a>
The sampling round on the show went over easy. Daymond John, founder of FUBU and one of the panel investors, called the crab-rangoon version "this is probably the best thing I've ever eaten in 16 years on this stage," while fellow panelist and inventor Lori Greiner, bowed out, saying she would rather stay a customer than a co-owner.&nbsp;
Corcoran spotted synergy with her other food investments and offered $150,000 for 15%.<a href="https://www.benzinga.com/personal-finance/24/09/40714364/survive-anything-kevin-oleary-claims-you-need-5-million-in-savings-heres-how-you-can-reach-that-"> Kevin O'Leary,</a> also known as "Mr. Wonderful," countered with 20%. The on-air haggling ended when Mark Cuban slid into Corcoran's offer, matching her money and bringing the total investment to $250,000 for a combined 20% stake.
Van Buskirk and Wellman cracked grins and accepted on camera, with Van Buskirk shouting "I can't wait to make them so much money." Cuban isn't exactly riding off into retirement. His <a href="https://healthee.com/pr/partnership-mark-cuban-cost-plus-drug-company/">Cost Plus Drug Co.</a> announced fresh distribution partnerships in April, pushing its catalog beyond 2,300 medications and saying transparent pricing has already helped patients save millions on generics.
Read Next: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
Image: Shutterstock

'I Definitely Love It,' Says Mark Cuban, As He Backs Deviled Egg Startup In His Final 'Shark Tank' Investment Worth $250,000

Shares of Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) are treading water on Monday. New reports indicate the company is initiating another round of layoffs impacting <a href="https://www.benzinga.com/25/03/44149088/disney-cuts-200-jobs-across-abc-and-tv-networks-amid-restructuring">several hundred employees globally</a>.
What To Know: Disney is reportedly cutting hundreds of roles. The cuts span multiple departments, including film and television marketing, publicity, casting, development and corporate finance, according to<a href="https://variety.com/2025/tv/news/disney-mass-layoffs-tv-film-finance-departments-1236415786/"> the Variety.</a>
The layoffs are part of Disney's ongoing efforts to streamline operations and boost efficiency across its sprawling media and entertainment business. While no teams are being eliminated in full, the reductions will reportedly impact staff in both domestic and international roles. 
The fresh round of job cuts follows multiple rounds of layoffs over the past year, including nearly 200 job cuts in TV and ABC News in March and around 300 corporate roles slashed in September 2024.
The efficiency push comes as Disney continues to restructure under CEO Bob Iger, who returned to the helm in late 2022 and led a major cost-cutting effort in 2023 that resulted in more than 8,000 job losses. The current cuts appear to be more targeted.
Despite the layoffs, Disney's recent financial performance has remained strong. The company beat Wall Street earnings expectations for the first quarter of 2025 and maintained guidance for the full fiscal year when it <a href="https://www.benzinga.com/25/05/45251203/disney-rides-strong-subscriber-growth-and-movie-hits-lifts-forecast-with-1-billion-streaming-goal">reported results</a> last month. Management projected a 16% increase in earnings per share and guided for double-digit growth in operating income for both the entertainment and sports segments, along with 6% to 8% growth in its parks and consumer products division.
&#8220;Our outstanding performance this quarter—with adjusted EPS up 20% from the prior year driven by our Entertainment and Experiences businesses—underscores our continued success building for growth and executing across our strategic priorities,&#8221; Iger said in May.
DIS price Action: Walt Disney shares were down 0.15% at $112.87 at the time of publication Monday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/06/45724821/trumps-manufacturing-narrative-weakens-as-may-data-shows-sharper-contraction-stubborn-inflation">Trump&#8217;s Manufacturing Narrative Weakens As May Data Shows Sharper Contraction, Stubborn Inflation </a></li>
</ul>
Image via Shutterstock.

Movers

What's Going On With Disney Stock Monday?

Shanghai-based NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) will likely provide a glimpse at the electric vehicle sector and new car brands when it releases its first-quarter financial results on Tuesday <a href="https://www.benzinga.com/earnings">before the market opens</a>.
Earnings Estimates: Analysts expect first-quarter revenue of $1.73 billion—up from $1.37 billion in last year's first quarter. 
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0602">According to Benzinga Pro</a>, NIO missed analyst estimates for revenue in four straight quarters and six of the last seven quarters overall, 
Analysts also anticipate a loss of 37 cents per share, compared to a loss of 33 cents per share in last year's first quarter, as <a href="https://www.gurufocus.com/news/2902405/nio-nio-anticipates-strong-q1-performance-with-revenue-surge">reported </a>by GuruFocus. The company has beaten analyst earnings per share in four of the last six quarters overall.
Guidance <a href="https://www.benzinga.com/25/03/44433594/nio-misses-revenue-estimates-lowers-q1-forecast-amid-stronger-competition-in-ev-market">from the company</a> calls for revenue to be in a range of $1.694 billion to $1.762 billion.
Read Also: <a href="https://www.benzinga.com/general/travel/25/05/45611551/gary-black-says-price-war-by-byd-threatens-tesla-dismisses-elon-musks-comeback-as-non-event">Gary Black Says Price War By BYD Threatens Tesla — Dismisses Elon Musk&#8217;s Comeback As &#8216;Non-Event&#8217;</a>
Key Items to Watch: NIO delivered 89,225 vehicles year-to-date, a figure that is up 34.7% from last year.
For May, <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45717955/chinas-nio-clocks-13-deliveries-growth-in-may-tesla-lags">the EV company reported</a>:
<ul class="wp-block-list">
<li>I23,231 vehicles delivered, up 13.1% year-over-year.</li>
<li>13,270 Nio brand deliveries, </li>
<li>6,281 ONVO deliveries</li>
<li>3,680 FIREFLY deliveries.</li>
</ul>
<a href="https://www.benzinga.com/25/05/45134925/chinese-ev-companies-see-huge-april-growth-xpeng-surges-273-in-deliveries">In April,</a> the company reported 23,900 deliveries, which is up 53% compared to last year. ONVO deliveries were 4,400, and FIREFLY had begun the initial deliveries.
ONVO and FIREFLY, the company's family-oriented and smaller high-end vehicles, respectively, are contributing to its strong delivery growth.
These new brands allow Nio to target more consumers and come after the company led the way as the top electric vehicle company in China for vehicles priced over RMB300,000.
ONVO brand, targeting the mainstream mass market, will concentrate on increasing its sales volume and enriching its product portfolio. Firefly's model will be officially launched and begin deliveries in April, serving as a key driver for our future international expansion," Nio CEO William Bin Li said after fourth-quarter results.
With deliveries already reported for April and May, investors and analysts will likely focus on the company&#8217;s guidance for the rest of the fiscal year and any commentary on tariffs.
Chinese stocks like Nio have been <a href="https://www.benzinga.com/government/regulations/25/05/45348699/us-listed-chinese-stocks-rally-as-countries-agree-to-ease-import-tariffs">highly volatile</a> due to tariffs placed on imports into the U.S. A recent pause to higher tariffs on Chinese imports has helped boost Chinese stocks temporarily.
NIO Price Action: Nio stock was down 0.71% to $3.52 at last check on Monday, compared to a 52-week trading range of $3.02 to $7.71. It is down 23.2% year-to-date in 2025.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45585660/golden-cross-alert-rivian-breaks-out-even-as-nio-outsells-it-10-to-1">Golden Cross Alert: Rivian Breaks Out, Even As Nio Outsells It 10-To-1</a></li>
</ul>
Image: Shutterstock

Previews

NIO Q1 Earnings Preview: Chinese EV Shows Delivery Growth, Will Tariff Concerns Minimize?

Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) stock is trading higher on Monday after the company announced the launch of the latest enhancements to VMware <a href="https://www.benzinga.com//node/45720573">Tanzu Cloudhealth.</a>
The Details: Broadcom released Intelligent Assist, a generative artificial intelligence co-pilot designed to help financial operations teams better utilize the CloudHealth platform. 
The large language model-powered chatbot also allows users to generate custom reports and receive cloud-specific recommendations through natural language.
In addition, the company announced Smart Summary, a new feature that helps users quickly identify what cloud costs changed, why they changed and what actions can be taken in response.
&#8220;We are proud to officially introduce the general availability of the new CloudHealth experience at the FinOps X conference. Innovative, new AI-powered features like Intelligent Assist and Smart Summary provide users a greater ability to make sense of cloud data and reporting necessary to collaborate among teams to control cloud spend,&#8221; said Purnima Padmanabhan, general manager, Tanzu Division, Broadcom. 
&#8220;This product investment not only signifies our commitment to innovation, but also to Arrow Electronics, our strategic go-to-market partner focused on bringing CloudHealth to new markets and helping to further grow this business.&#8221;
What Else: The company is expected to report second-quarter earnings on June 5 after the markets closes. Analysts estimate earnings per share of $1.56 and revenue of $14.99 billion.
See Also: <a href="https://www.benzinga.com/markets/biotech/25/06/45730717/novocures-tumor-treating-fields-boosts-one-year-and-pain-free-survival-in-pancreatic-cancer-trial">NovoCure&#8217;s Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial</a>
AVGO Price Action: At the time of writing, Broadcom stock is trading 2.96% higher at $249.26, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwjM3-3FrNONAxXQpIkEHWENBnkQFnoECA4QAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro.</a>
Image: via Shutterstock

AVGO

Broadcom Stock Is Trading Higher Monday: What's Going On?

Management

Infrared Cameras Holdings, Inc. - Common Stock

MSAI

MultiSensor AI Appoints Asim Akram As CEO And President To Lead Strategic Growth Objectives, June 23, 2025

Let's be clear…&nbsp;There are no emergency rate cuts coming.
The economy is way too strong. So if you're betting on a Fed pivot to bail out your portfolio… don't.
Why do I say that? Because the data says it.
The market says it. Even bonds say it.
"Higher for longer" isn't a theory anymore. It's the base case.
Fed Funds Futures are now pricing in a near 100% chance the Fed pauses in June.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXfDqKxgbPIDhVG-nHukmb-wEfrn6lYg2G3S1asCZBOvUA-x5iByMYgaOR8TQzdinFBMI0j6gf_nR9cQw5oW3wb15XqwpHyBYod3TWSi3m_0Xbir6yB_gbhLi7ILSg85iTOmhp4EMA?key=9aRcG5tIW5wbjKgpchg-0g" alt="" /></figure>
Not only that… there's a 65% chance we only get two cuts all year. That's it. That's the story.
Not because inflation is spiraling out of control (thank goodness). But because the economy simply doesn't need rate cuts.
People are spending. The consumer is holding up. There's no hard landing to fix.
Q1 GDP dipped, but that was just frontloaded imports ahead of tariff hikes. Q2?
The Atlanta Fed is now forecasting +3.8% QoQ growth.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXcNjNv7p9GrWRhIvz7SSSl3M-a9vSlcqPjz2b6410mDkpSwlbGwZak5A12CSyxoIkPgmQHbHE1qLLUboLDdAvkDoaYeXptdj9d0gIBrIu1SP4tvtL9mfpkILqQfzvCVmPTyD89_Bg?key=9aRcG5tIW5wbjKgpchg-0g" alt="" /></figure>
That's not just resilience… that's strength. Why would the Fed stimulate into that?
It'd be like handing more candy to kids already bouncing off the walls.
So what do we do? We stay with long-term risk assets. We buy the dips. We don't let fear dictate strategy.
That doesn't mean we won't see corrections. But if the crowd starts panicking about recession again?
Fade it. That's exactly what we did on April 9, at the bottom.
We loaded up on $HOOD… and even took a swing at $ROBN, the REX Shares 2x levered Robinhood ETF.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXdmfMS4_zFvDkhEYnwXV0NkCh0Rk0hIJDpsAROdEUqmtm5fgf-Odjx8Jok_sqp-KHajC12Cms22liGRGfmViEf1OOIpe6GjHMNuyTSh8J9wk8Vbs8Q4JHu6pLYJrqnOU2ZheUHHgA?key=9aRcG5tIW5wbjKgpchg-0g" alt="" /></figure>
That trade worked. And it worked because we ignored the noise and trusted the data.
So stay sharp. Be cautious. Manage your risk.
But don't wait for the Fed to save you. Because this year, they won't.
&#x2A;&#x2A;
Welcome to the WOLF Financial Newsletter.
Join over 18,000 savvy investors building wealth and mastering advanced investing strategies live on Twitter Spaces. Subscribe below to be part of the action:
<a target="_blank" rel="noreferrer noopener" href="https://marketmadness-newsletter.beehiiv.com/subscribe">Subscribe</a>
WOLF Financial has driven liquidity, user growth, and brand awareness across TradFi and Crypto through marketing, advisory, and partnership services. See more&nbsp;<a href="https://wolf.financial/?utm_source=marketmadness-newsletter.beehiiv.com&amp;utm_medium=newsletter&amp;utm_campaign=new-post" target="_blank" rel="noreferrer noopener">Here</a>.

Equities

Long Ideas

Econ #s

Opinion

Federal Reserve

Markets

ETFs

The Fed Will Not Save Us This Year

Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) shares are trading higher Monday following reports that the company is preparing to launch a fully automated ad creation system powered by<a href="https://www.benzinga.com/markets/tech/25/06/45722563/mark-zuckerbergs-meta-to-offer-fully-automated-ai-based-ad-creation-by-2026-report\"> artificial intelligence by the end of 2026. </a>
What To Know: The move marks a significant step in CEO Mark Zuckerberg's broader strategy to expand the company's AI capabilities and transform how brands create and deliver advertisements.
According to <a href="https://www.wsj.com/tech/ai/meta-aims-to-fully-automate-ad-creation-using-ai-7d82e249">The Wall Street Journal</a>, the planned system will allow businesses to upload a product image and define a budget, after which Meta's AI will handle the rest, generating visuals, videos and ad copy, selecting the target audience on Facebook and Instagram and even recommending budget adjustments. The system is also expected to tailor ad content in real time based on user-specific data such as location.
This represents a major evolution from Meta's current tools, which already use AI to produce minor variations of ads and optimize targeting. Meta has also launched an "Early Release" program, giving select advertisers early access to its generative AI tools, which are already delivering positive results.
While the shift toward full automation has raised concerns among some large brands about losing control over messaging and strategy, Meta's advertising business continues to perform strongly. In its most recent earnings report, the company noted a 5% increase in ad impressions and a 10% rise in average price per ad year-over-year.
The broader context includes trade and policy uncertainty, including potential impacts from President Donald Trump's newly announced tariffs, which could affect ad budgets across the tech sector. Nevertheless, Meta's push into AI-driven ad solutions may help the company and its clients adapt to evolving economic and regulatory conditions.
META Price Action: Meta shares were up 3.74% at $671.88 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45728618/stocks-stall-commodities-rocket-as-trade-geopolitical-tensions-resume-whats-driving-market-monday">Stocks Stall, Commodities Rocket As Trade, Geopolitical Tensions Resume: What&#8217;s Driving Market Monday? </a></li>
</ul>
Image Via Shutterstock.

What's Going On With Meta Shares Today?

Edward and Ludmila Smolyansky, beneficial owners of approximately 27% of Lifeway Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LWAY#NASDAQ">LWAY</a>), today issued a statement expressing serious concerns about the company's Q1 2025 performance and what they describe as the Board's ongoing pattern of poor governance and misaligned priorities.
Although Lifeway reported a 44% year-over-year increase in GAAP earnings per share, Mr. Smolyansky emphasized that this was entirely due to a one-time $3.4 million gain from an investment sale, not from any improvement in the company's underlying kefir business. He and Mrs. Smolyansky cited several troubling operational trends, including:
<ul>
<li>Income from operations declined nearly 55% year-over-year. &nbsp;</li>
<li>Operating margin fell to approximately 3.4%, down from 7.9% in Q1 2024. &nbsp;</li>
<li>Net sales increased only 3.3% year-over-year and declined 1.8% sequentially from Q4 2024. &nbsp;</li>
<li>Revenue from the 2021 acquisition of Glen Oaks, a&nbsp;Laguna Beach, California-based drinkable yogurt company lacking any tangible assets, has declined approximately 50% to date. Notably, only two Directors – Edward and Ludmila Smolyansky – voted against this acquisition. &nbsp;</li>
<li>Selling expenses rose sharply – up 27% year-over-year and 35% from Q4, without a corresponding increase in sales. &nbsp;</li>
<li>Gross margin contracted by 180 basis points to 24.0%;&nbsp;SG&amp;A expenses climbed to 20.2% of sales. &nbsp;</li>
<li>Insider stock sales by Director&nbsp;Pol Sikar and CEO Julie Smolyansky following the May 15, 2025 earnings release raised additional concerns about management's confidence in the company's outlook.</li>
</ul>
Ludmila and Edward Smolyansky also criticized the Board's governance and oversight, highlighted by its handling of the Danone offer, the subsequent attempt to nullify the Company's 1999 Stockholder Agreement with Danone, and the award of $8.5 million in cash and shares granted to CEO/Chair Julie Smolyansky by the Board shortly thereafter. The Smolyanskys also shared their views that:
<ul>
<li>The combined CEO/Chair role, while occupied by Ms. Smolyansky, has been a significant governance failure resulting in lack of independent oversight; &nbsp;</li>
<li>The handling of&nbsp;Danone's offer and subsequent attempt to sever ties may have market implications that the Board has failed to consider; &nbsp;</li>
<li>The questionable compensation awards granted to CEO/Chair Julie&nbsp;Smolyansky at the end of 2024 were in flagrant opposition to shareholder sentiment conveyed at last year's annual meeting; and &nbsp;</li>
<li>Only a reconstituted Board with an independent committee tasked with assessing strategic alternatives and potentially re-engaging with&nbsp;Danone, in the manner deserving of a 25-year investor and partner, can produce a more favorable outcome for shareholders.</li>
</ul>

LWAY

27% Holders Of Lifeway Foods, Edward And Ludmila Smolyansky, Criticize Q1 2025 Results And Board Governance, Citing Weak Operating Performance Masked by One-Time Gain, Declining Margins, Rising Costs, Insider Stock Sales, And Mismanagement Of Danone Offer; Calls For Board Overhaul And Independent Review Of Strategic Alternatives

MYGN

Myriad Genetics shares are trading higher after the company announced new data from its MONSTAR-SCREEN 3 study.

Financial giants have made a conspicuous bearish move on Roku. Our analysis of options history for Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) revealed 8 unusual trades.
Delving into the details, we found 25% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $217,950, and 5 were calls, valued at $201,240.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $60.0 and $100.0 for Roku, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Roku options trades today is 802.62 with a total volume of 491.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Roku's big money trades within a strike price range of $60.0 to $100.0 over the last 30 days.
<h3>Roku 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748890891_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ROKU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$5.6</td>
<td>$5.45</td>
<td>$5.6</td>
<td>$75.00</td>
<td>$112.0K</td>
<td>272</td>
<td align="right">3</td>
</tr>
<tr>
<td>ROKU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$18.5</td>
<td>$18.25</td>
<td>$18.45</td>
<td>$85.00</td>
<td>$55.3K</td>
<td>644</td>
<td align="right">36</td>
</tr>
<tr>
<td>ROKU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$14.05</td>
<td>$13.95</td>
<td>$14.05</td>
<td>$75.00</td>
<td>$50.5K</td>
<td>121</td>
<td align="right">37</td>
</tr>
<tr>
<td>ROKU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$2.77</td>
<td>$2.71</td>
<td>$2.71</td>
<td>$75.00</td>
<td>$48.7K</td>
<td>2.6K</td>
<td align="right">205</td>
</tr>
<tr>
<td>ROKU</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$5.1</td>
<td>$4.75</td>
<td>$4.95</td>
<td>$100.00</td>
<td>$44.5K</td>
<td>1.7K</td>
<td align="right">90</td>
</tr>
</tbody>
</table>

<h3>About Roku</h3>
Roku enables consumers to stream television programming. It has more than 90 million streaming households and provided 127 billion streaming hours in 2024. Roku is the top streaming operating system in the US, reaching more than half of broadband households, according to the company. Roku's OS is built into streaming devices and televisions that Roku sells and on connected televisions from other manufacturers that license Roku's name and software. Roku also operates the Roku Channel, a free, ad-supported streaming television platform that offers a mix of on-demand and live television programming. Roku generates revenue primarily from selling devices, licensing, and advertising, and it receives fees from subscription streaming platforms that sell subscriptions through Roku.
In light of the recent options history for Roku, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Roku Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 1,433,147, the ROKU's price is up by 1.8%, now at $73.77. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 59 days.</li>
</ul>
<h3>Professional Analyst Ratings for Roku</h3>
In the last month, 4 experts released ratings on this stock with an average target price of $85.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $88. 
&#x2A; In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $88. 
&#x2A; An analyst from JMP Securities downgraded its action to Market Outperform with a price target of $95. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Neutral rating for Roku, targeting a price of $68. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Roku options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

ROKU

Spotlight on Roku: Analyzing the Surge in Options Activity

Financial giants have made a conspicuous bullish move on Capital One Finl. Our analysis of options history for Capital One Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) revealed 9 unusual trades.
Delving into the details, we found 55% of traders were bullish, while 22% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $2,211,747, and 3 were calls, valued at $193,500.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $125.0 and $200.0 for Capital One Finl, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Capital One Finl options trades today is 567.62 with a total volume of 5,519.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Capital One Finl's big money trades within a strike price range of $125.0 to $200.0 over the last 30 days.
<h3>Capital One Finl Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748890886_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>COF</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$4.3</td>
<td>$3.7</td>
<td>$4.0</td>
<td>$175.00</td>
<td>$2.0M</td>
<td>1.2K</td>
<td>5.1K</td>
</tr>
<tr>
<td>COF</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$77.9</td>
<td>$76.0</td>
<td>$76.0</td>
<td>$125.00</td>
<td>$114.0K</td>
<td>2</td>
<td>15</td>
</tr>
<tr>
<td>COF</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$2.75</td>
<td>$2.1</td>
<td>$2.2</td>
<td>$195.00</td>
<td>$44.0K</td>
<td>1.4K</td>
<td>200</td>
</tr>
<tr>
<td>COF</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$14.0</td>
<td>$13.8</td>
<td>$13.8</td>
<td>$180.00</td>
<td>$38.6K</td>
<td>506</td>
<td>67</td>
</tr>
<tr>
<td>COF</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$14.2</td>
<td>$14.0</td>
<td>$14.0</td>
<td>$180.00</td>
<td>$36.4K</td>
<td>506</td>
<td>26</td>
</tr>
</tbody>
</table>

<h3>About Capital One Finl</h3>
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.
Having examined the options trading patterns of Capital One Finl, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Capital One Finl Standing Right Now?</h3>
<ul>
<li>With a volume of 2,555,736, the price of COF is up 1.28% at $191.57. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 50 days.</li>
</ul>
<h3>Expert Opinions on Capital One Finl</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $233.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on Capital One Finl with a target price of $233. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Capital One Finl with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Looking At Capital One Finl's Recent Unusual Options Activity

Investors with a lot of money to spend have taken a bullish stance on Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with HD, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 18 uncommon options trades for Home Depot.
This isn't normal.
The overall sentiment of these big-money traders is split between 38% bullish and 33%, bearish.
Out of all of the special options we uncovered, 7 are puts, for a total amount of $305,805, and 11 are calls, for a total amount of $517,582.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $250.0 to $400.0 for Home Depot over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Home Depot's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Home Depot's significant trades, within a strike price range of $250.0 to $400.0, over the past month.
<h3>Home Depot Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748890880_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$12.25</td>
<td>$11.85</td>
<td>$11.85</td>
<td>$380.00</td>
<td>$118.5K</td>
<td align="right">920</td>
<td align="right">140</td>
</tr>
<tr>
<td>HD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$5.7</td>
<td>$5.65</td>
<td>$5.65</td>
<td>$365.00</td>
<td>$88.7K</td>
<td align="right">768</td>
<td align="right">37</td>
</tr>
<tr>
<td>HD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$6.4</td>
<td>$6.3</td>
<td>$6.4</td>
<td>$340.00</td>
<td>$55.2K</td>
<td align="right">347</td>
<td align="right">147</td>
</tr>
<tr>
<td>HD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/13/25</td>
<td>$11.0</td>
<td>$9.9</td>
<td>$11.0</td>
<td>$370.00</td>
<td>$55.0K</td>
<td align="right">71</td>
<td align="right">50</td>
</tr>
<tr>
<td>HD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$17.25</td>
<td>$17.0</td>
<td>$17.0</td>
<td>$370.00</td>
<td>$51.0K</td>
<td align="right">411</td>
<td align="right">32</td>
</tr>
</tbody>
</table>

<h3>About Home Depot</h3>
Home Depot is the world's largest home improvement specialty retailer, operating 2,350 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the US, Canada, and Mexico. Its stores offer building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of Interline Brands in 2015 allowed Home Depot to enter the MRO business, which has been expanded through the tie-up with HD Supply (2020). The additions of the Company Store brought textiles to the lineup, and the 2024 tie-up with SRS will help grow professional demand in roofing, pool and landscaping projects.
In light of the recent options history for Home Depot, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Home Depot's Current Market Status</h3>
<ul>
<li>Trading volume stands at 1,614,723, with HD's price down by -0.3%, positioned at $367.17.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 71 days.</li>
</ul>
<h3>Expert Opinions on Home Depot</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $439.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Telsey Advisory Group has decided to maintain their Outperform rating on Home Depot, which currently sits at a price target of $455. 
&#x2A; An analyst from TD Securities downgraded its action to Buy with a price target of $470. 
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Outperform rating for Home Depot, targeting a price of $435. 
&#x2A; An analyst from Baird persists with their Outperform rating on Home Depot, maintaining a target price of $425. 
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Home Depot with a target price of $410. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Home Depot with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Home Depot Options Trading: A Deep Dive into Market Sentiment

Ratings for Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $505.0, a high estimate of $529.00, and a low estimate of $478.00. Highlighting a 0.86% decrease, the current average has fallen from the previous average price target of $509.38. 
<img src="https://www.benzinga.com/files/images/story/2025/1748890867_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Elevance Health by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$522.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$478.00</td>
<td>$478.00</td>
</tr>
<tr>
<td>Jason Cassorla</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$518.00</td>
<td>$518.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$485.00</td>
<td>$485.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$522.00</td>
<td>$512.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$529.00</td>
<td>$625.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$510.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Jason Cassorla</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$518.00</td>
<td>-</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$505.00</td>
<td>$455.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Elevance Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Elevance Health compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Elevance Health's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Elevance Health's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ELV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Elevance Health analyst ratings.</a>
<h2>All You Need to Know About Elevance Health</h2>
Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 46 million medical members as of December 2024. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.
<h3>Breaking Down Elevance Health's Financial Performance</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Elevance Health displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 14.83%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 4.46%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Elevance Health's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.21%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Elevance Health's ROA stands out, surpassing industry averages. With an impressive ROA of 1.85%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.71, Elevance Health adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Beyond The Numbers: 9 Analysts Discuss Elevance Health Stock

11 analysts have expressed a variety of opinions on Samsara (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IOT#NYSE">IOT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $49.27, a high estimate of $54.00, and a low estimate of $42.00. A decline of 5.41% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1748890860_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Samsara. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Jester</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$54.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>James Fish</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$50.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>James Fish</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$44.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Daniel Jester</td>
<td>BMO Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>James Fish</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$54.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Junaid Siddiqui</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$42.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Daniel Jester</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$48.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$51.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Samsara. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Samsara compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Samsara's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Samsara's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/IOT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Samsara analyst ratings.</a>
<h2>Discovering Samsara: A Closer Look</h2>
Samsara Inc provides an end-to-end solution for operations. The company's Connected Operations Platform consolidates data from its IoT devices and a growing ecosystem of connected assets and third-party systems, and makes it easy for organizations to access, analyze, and act on data insights using its cloud dashboard, custom alerts and reports, mobile apps, and workflows.. The company derives almost all of its revenue from subscription services. Geographically, it derives a majority of its revenue from the United States. The company's customers ranges from small and medium-sized businesses to state and local governments.
<h3>Financial Milestones: Samsara's Journey</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3M period, Samsara showcased positive performance, achieving a revenue growth rate of 25.34% as of 31 January, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Samsara's net margin excels beyond industry benchmarks, reaching -3.23%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Samsara's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -1.08%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Samsara's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.58%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Samsara's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.08.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 11 Analyst Projections For Samsara

Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $7.14, along with a high estimate of $9.00 and a low estimate of $5.00. This upward trend is evident, with the current average reflecting a 13.51% increase from the previous average price target of $6.29.
<img src="https://www.benzinga.com/files/images/story/2025/1748890850_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive Taysha Gene Therapies is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$8.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$6.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$9.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$9.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.00</td>
<td>$6.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Taysha Gene Therapies. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Taysha Gene Therapies compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Taysha Gene Therapies's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TSHA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Taysha Gene Therapies analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Taysha Gene Therapies's Background</h2>
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
<h3>Unraveling the Financial Story of Taysha Gene Therapies</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Negative Revenue Trend: Examining Taysha Gene Therapies's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -32.51% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Taysha Gene Therapies's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -935.23%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Taysha Gene Therapies's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -34.02%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -14.41%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Taysha Gene Therapies's debt-to-equity ratio surpasses industry norms, standing at 1.11. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TSHA

Where Taysha Gene Therapies Stands With Analysts

Broadstone Net Lease (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BNL#NYSE">BNL</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $19.6, a high estimate of $21.00, and a low estimate of $17.00. Holding firm without variation, the current average remains at the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2025/1748890842_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Broadstone Net Lease is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitch Germain</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$21.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Michael Goldsmith</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$17.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Ki Bin Kim</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$18.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Mitch Germain</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$21.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Mitch Germain</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$21.00</td>
<td>$21.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Broadstone Net Lease. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Broadstone Net Lease compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Broadstone Net Lease's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Broadstone Net Lease's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BNL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Broadstone Net Lease analyst ratings.</a>
<h2>Delving into Broadstone Net Lease's Background</h2>
Broadstone Net Lease Inc is an internally managed real estate investment trust that invests in, owns, and manages single-tenant commercial real estate properties that are net leased on a long-term basis to a diversified group of tenants. The company has selectively invested in net leased assets in the industrial, healthcare, restaurant, retail, and office property types. The company focuses on investing in real estate that is operated by creditworthy single tenants in industries characterized by positive business drivers and trends. The company targets properties that are an integral part of the tenants' businesses and are therefore opportunities to secure long-term net leases.
<h3>Broadstone Net Lease's Economic Impact: An Analysis</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Broadstone Net Lease's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 3.15%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Real Estate sector.
Net Margin: Broadstone Net Lease's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 15.12% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Broadstone Net Lease's ROE stands out, surpassing industry averages. With an impressive ROE of 0.55%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Broadstone Net Lease's ROA stands out, surpassing industry averages. With an impressive ROA of 0.31%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.69, Broadstone Net Lease adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Broadstone Net Lease Stands With Analysts

Earnings

Press Releases

Click Holdings Limited Reports Strong Growth in the First Half of 2024 Financial Results

General

CLICK announced to expand service to the Community Care Service Voucher scheme for elderly (CCSV scheme) in Hong Kong

Click announced the CEO Statement

CLIK Announces Strategic Acquisition of Leading Nursing Care Competitor, Expanding Market Presence and Talent Pool

CLIK Announces Pricing of $8.28 Million Public Offering of Ordinary Shares

CLIK Announces Closing of $8.28 Million Public Offering of Ordinary Shares

CLIK Announces Acquisition of Remaining 75% Equity Interest in Leading Nursing Care Competitor, Solidifying Market Leadership and Expanding Revenue Base

CLIK announces to collaborate with an advanced technology company under the Tencent SSV initiatives, to jointly promote 24-hour instant device service for senior citizens in Hong Kong; and also announces change to board composition

Comments

Click Holdings

空売り

Click Holdings (NASDAQ:CLIK) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル